SkinVive: What It Is, Cost and Results

SkinVive by Juvéderm is an injectable gel made of hyaluronic acid, the same material family as the Juvéderm fillers.

FDA approved it on May 11, 2023, under PMA P110033 supplement S059, as an intradermal injection — delivered into the skin itself — to improve facial skin smoothness of the cheeks in adults over 21.

On June 11, 2026, FDA expanded the approval to intradermal and/or subdermal injection to reduce neck lines, for improvement of neck appearance, also in adults over 21.

Allergan calls SkinVive a "hyaluronic acid microdroplet injectable" that adds hydration into the skin, and the microdroplet wording matches the approved technique: an intradermal injection, gel placed within the skin.

In the pivotal trial, the gel studied was Allergan's 12 mg/mL hyaluronic acid formulation with 0.3% lidocaine.

You will see SkinVive called a "skin booster." Allergan markets it as a skin-quality treatment rather than a volumizer, and the approval wording matches that framing: smoothness, not shape.

Legally, it sits in the filler family: FDA approved SkinVive under PMA P110033, the Juvéderm filler premarket approval, and it is a hyaluronic acid gel like them.

Practically, it is not used the way a volumizing filler is.

The other Juvéderm fillers are approved for areas where placement is about fullness and contour — Allergan describes its six-filler collection as covering the cheeks, chin, temples, smile lines, lips, under-eyes and jawline.

SkinVive's approved purpose is smoother cheek skin, delivered as small intradermal droplets, and Allergan says it is a skin-quality treatment rather than a volumizer.

For how the volumizing fillers compare with each other, see dermal fillers, the category overview.

Three things SkinVive is not: it is not a volume filler; it is not approved for the lips or the under-eyes; and Allergan's published duration figure is 6 months with optimal treatment, not a year.

Those points come from FDA's approval record and Allergan's SkinVive question-and-answer page.

SkinVive has two FDA-approved uses, both in adults over 21.

The first is cheek skin smoothness: the label indication is intradermal injection to improve facial skin smoothness of the cheeks.

The second is newer: since June 11, 2026, SkinVive is also indicated for intradermal and/or subdermal injection to reduce neck lines, for improvement of neck appearance.

The cheek evidence comes from a randomized US study in which 131 participants received the gel — published under Allergan's product code VYC-12L, its 12 mg/mL hyaluronic acid gel with 0.3% lidocaine — and 71 received no treatment.

At month 1, 57.9% of treated participants had improved at least one grade in cheek smoothness, against 4.5% of untreated controls, and responder rates stayed consistent through the 6-month follow-up.

The median total volume, initial plus touch-up treatments combined, was 4.0 mL for both cheeks, in a range of 0.8–6.0 mL — a trial figure, not a standard dose and not a promise of your result.

For what results look like, see SkinVive before and after.

Uses beyond the cheeks and neck are off-label.

SkinVive is not FDA-approved for the lips or the under-eyes, and the Important Safety Information on Allergan's SkinVive site states that the product is intended for improving skin smoothness of the cheeks and that safety and effectiveness in other areas of the body have not been established.

Fuller lips is not a goal SkinVive's label serves — lip filler has its own guide, including which products hold lip approvals.

The neck-lines approval is recent enough to explain some confusion.

FDA's general dermal-filler page, with content current as of 07/06/2023, listed the neck among the areas no filler was approved for; that page predates SkinVive's 2026 neck-lines approval, so neck-lines treatment is now on-label for SkinVive specifically, while the nose remains an area with no FDA-approved filler indication.

And if you see SkinVive described as cheeks-only, that may be why: as of October 2026, the Important Safety Information on Allergan's SkinVive site still described the cheek use only, without the 2026 neck-lines indication.

Allergan does not publish a price on its Juvéderm FAQ; it says pricing varies by the Juvéderm product used, the amount used and the provider.

Our sources carry no national average price for SkinVive, and we will not invent one — the numbers that matter are the quotes at the clinics you contact.

For the full price breakdown, see how much SkinVive costs.

Category data is the only national reference point.

ASPS's dermal-filler cost page lists an average cost of $715 for hyaluronic acid fillers, per its latest statistics.

Read that figure for what it is: a national average physician fee, per procedure — typically one syringe — not a med spa price and not specific to SkinVive.

The variables Allergan names are the shape of a SkinVive quote: which Juvéderm product, how much of it, and whose hands — the practice's own pricing.

The trial's median of 4.0 mL for both cheeks, initial and touch-up treatments combined, gives a sense of the quantities studied — a trial figure, not a standard amount to expect on a quote.

Allergan also runs a loyalty program, Allē: its SkinVive site says members earn points on SkinVive treatments.

Point values and program terms change, so check the current terms before you book.

Allergan says SkinVive results last for 6 months with optimal treatment.

That is the maker's figure, and it arrives with the maker's own condition attached: "optimal treatment" is Allergan's wording, not a schedule our sources define — ask a practice you are considering what they count as optimal treatment.

We found no longer duration figure for SkinVive in the sources we check.

The trial is a separate source.

In the VYC-12L study, cheek-smoothness responder rates stayed consistent through the 6-month follow-up — a trial observation, not a test of Allergan's duration figure.

We have no confirmed study figure for how long results go on past that point, so we won't quote one.

What the 6-month figure means for your calendar is a conversation with your provider: our sources do not pin down how clinics time retreatment.

Ask how the practice schedules repeat sessions and what it counts as optimal treatment.

The Important Safety Information on Allergan's SkinVive site lists the most commonly reported side effects as redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration and itching.

Most side effects resolve within 7 days, per the same safety information.

It also gives aftercare wording: it advises minimizing strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment.

Our sources do not give a percentage rate for these side effects, so we won't quote one here.

If a side effect worries you or lasts longer than that safety information suggests, contact the provider who treated you.

Who may inject SkinVive is set by state law, not by this page.

AmSpa, the med spa trade association, explains the practice-of-medicine logic it gives for botulinum toxin: the injection falls under the practice of medicine because an FDA legend (prescription) drug is being used to affect living tissue, so it must be done by a physician, an independent-practice NP or another licensed professional acting within their scope, under rules that vary by state.

For the delegation picture, AmSpa's general description of med spa practice is that NPs inject with documented training under a collaborative agreement or full practice authority, and that RNs — and, in some states, LPNs/LVNs or medical assistants — can perform treatment with injectable toxins and dermal fillers with documented training, pursuant to a patient examination and treatment order from a physician (or a delegated PA/NP), with the physician on site or promptly reachable.

Unlicensed people cannot inject on their own, per the same description.

This is AmSpa's generic picture, not every state's rule; the specifics genuinely differ from state to state.

Two product-specific questions belong in a SkinVive consultation.

First: is the area you are asking about an approved use — cheek smoothness or neck lines — or an off-label one?

Second: who exactly will do the injecting, and what training do they have with this product?

For the fuller vetting routine — credentials, red flags and the questions worth asking before any treatment — see how to choose a med spa, and the guide to med spa injector credentials for who does what in the treatment room.